SCHEMBL21149372

SCHEMBL21149372

CC1(C)O[C@H]2[C@@H](O1)[C@@H](CN1CCN(c3cccc(O)c3)CC1)O[C@@H]1OC(C)(C)O[C@@H]12

nearest known ligand 0.50

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 2/20 0.50
▸ DRD3 P35462 1/20 0.44
▸ HTR7 P34969 11/20 0.42
▸ OPRM1 P35372 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ ESR1 P03372 1/20 0.37
▸ ESR2 Q92731 1/20 0.37
▸ DRD4 P21917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21149371 1.00 DRD2 (0.50) DRD2DRD3HTR7OPRM1ALDH1A1
SCHEMBL21148637 0.87 ALDH1A1 (0.41) DRD2DRD3HTR7ALDH1A1DRD4
SCHEMBL24137899 0.87 ALDH1A1 (0.41) DRD2DRD3HTR7ALDH1A1DRD4
SCHEMBL21148820 0.81 DRD4 (0.41) DRD2DRD3ALDH1A1DRD4
SCHEMBL21148318 0.78 KCNH2 (0.36) DRD2DRD3ALDH1A1DRD4
SCHEMBL21148317 0.78 KCNH2 (0.36) DRD2DRD3ALDH1A1DRD4
SCHEMBL21148822 0.77 MAPT (0.42) DRD2ALDH1A1DRD4
SCHEMBL24145313 0.75 DRD2 (0.42) DRD2DRD3HTR7OPRM1ALDH1A1
SCHEMBL10190784 0.69 CA2 (0.45) ALDH1A1
SCHEMBL3453730 0.68 DRD2 (1.00) DRD2DRD3HTR7OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 DRD2 4570/4885DRD3 4609/4885HTR7 3180/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 DRD2 4570/4885DRD3 4609/4885HTR7 3180/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 DRD2 4570/4885DRD3 4609/4885HTR7 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback